Participation in cancer treatment clinical trials is a key measure for delivery of quality cancer care, yet adult trial participation in the U.S. remains under 3%, with even lower participation rates among ethnic and racial minorities and people over 65. Whether focusing on studies sponsored by the National Cancer Institute or industry, institutions often struggle in isolation to achieve efficient and effective accrual.
The Commission on Cancer’s 2015 guidelines dictate higher accrual rates for all cancer treating institutions, so it is more important than ever to use effective accrual practices that are grounded in evidence. Unfortunately, there are few evidence-based practices to help sites achieve higher accrual rates. ENACCT is creating this evidence through its leadership of the Cancer Clinical Trial Collaborative Learning Network (CCTCLN). The CCTCLN is built upon the successful work of the National Pilot Collaborative completed in 2012. (Read more here). The goal of the CCTCLN is to further the goal of the Pilot: to identify practical, patient-centered approaches to increase accrual overall and, in particular, for ethnic /racial minorities and people over 65.
ENACCT is now accepting applications for the next generation of this network to assist cancer centers and community oncology practices in becoming more effective and efficient in their approaches to recruitment, accrual and retention. (See www.enacct.org for more details.). The Learning Network Can Help Cancer Centers and Community Oncology Practices by:
Institutions who join this Network will participate in a unique opportunity for improving their accrual practices in a cost-effective manner. Applications are open now and are due June 21 2013. (See www.enacct.org for more details.)
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.